Science Explorer Back to mapMap

Most cited papers from Children's Oncology Group

What are the most cited papers from Children's Oncology Group?

The most cited paper from Children's Oncology Group is "Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid" (Katherine K. Matthay, Judith Grob Villablanca, Robert C. Seeger et al., 1999), with 1,915 citations. Next come "Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia" (1,459) and "Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia" (1,391).

Showing 50 of 60 papers. Every paper with more than 306 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid Katherine K. Matthay, Judith Grob Villablanca, Robert C. Seeger et al. · New England Journal of Medicine Open access 14 Oct 1999 1,915
2 Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia Charles Grenfell Mullighan et al. · New England Journal of Medicine Open access 7 Jan 2009 1,459
3 Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia Kathryn G. Roberts et al. · New England Journal of Medicine Open access 11 Sep 2014 1,391
4 The International Neuroblastoma Pathology Classification (the Shimada system) Hiroyuki Shimada, Inge M. Ambros, Louis P. Dehner et al. · Cancer 15 Jul 1999 1,042
5 The Third Intergroup Rhabdomyosarcoma Study. W M Crist, E. A. Gehan, A H Ragab et al. · Journal of Clinical Oncology Mar 1995 1,013
6 Activating mutations in ALK provide a therapeutic target in neuroblastoma Rani E. George et al. · Nature Open access Oct 2008 903
7 The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions Hamid Bolouri et al. · Nature Medicine Open access 11 Dec 2017 900
8 Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study Michael J. Borowitz, Meenakshi Devidas, Stephen P. Hunger et al. · Blood Open access 4 Apr 2008 849
9 Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group Paul A. Meyers, Cindy L. Schwartz, Mark Krailo et al. · Journal of Clinical Oncology Open access 30 Jan 2008 756
10 Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort Sigbjørn Smeland et al. · European Journal of Cancer Open access 27 Jan 2019 748
11 The intergroup rhabdomyosarcoma study-II Harold M. Maurer et al. · Cancer Mar 1993 740
12 Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate Paul A. Meyers et al. · Journal of Clinical Oncology Open access 18 Mar 2005 724
13 Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study Yaël P. Mossé, Megan S. Lim, Stephan D. Voss et al. · The Lancet Oncology Open access 17 Apr 2013 714
14 A Comparison of Conservative and Aggressive Transfusion Regimens in the Perioperative Management of Sickle Cell Disease Elliott P. Vichinsky, Charles M. Haberkern, Lynne Neumayr et al. · New England Journal of Medicine Open access 27 Jul 1995 657
15 Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study Kayla L. Nguyen, Meenakshi Devidas, Cheng Sc et al. · Leukemia Open access 25 Sep 2008 592
16 Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma Edward F. Attiyeh, Wendy B. London, Yaël P. Mossé et al. · New England Journal of Medicine Open access 23 Nov 2005 580
17 Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia Richard C. Harvey, Charles Grenfell Mullighan, I‐Ming Chen et al. · Blood Open access 5 Feb 2010 576
18 Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations Thomas F. Eleveld et al. · Nature Genetics Open access 29 Jun 2015 568
19 JAK mutations in high-risk childhood acute lymphoblastic leukemia Charles Grenfell Mullighan et al. · Proceedings of the National Academy of Sciences Open access 22 May 2009 563
20 Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial Neyssa M. Marina et al. · The Lancet Oncology Open access 31 Aug 2016 559
21 Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification-an intergroup rhabdomyosarcoma study William A. Newton, Edmund A. Gehan, Bruce L. Webber et al. · Cancer 15 Sep 1995 559
22 Second Neoplasms after Acute Lymphoblastic Leukemia in Childhood Joseph P. Neglia, Anna T. Meadows, Leslie L. Robison et al. · New England Journal of Medicine Open access 7 Nov 1991 550
23 What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies Wendy Stock, Mei K. L. La, Ben L. Sanford et al. · Blood Open access 24 May 2008 538
24 Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group Meredith S. Irwin, Arlene H. Naranjo, Fan F. Zhang et al. · Journal of Clinical Oncology Open access 28 Jul 2021 505
25 A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study Vassilios I. Avramis, Susan Sencer, Antonia P. Periclou et al. · Blood 15 Mar 2002 501
26 Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease Cameron K. Tebbi, Wendy B. London, Debra L. Friedman et al. · Journal of Clinical Oncology Open access 8 Feb 2007 493
27 Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531 Alan S. Gamis, Todd A. Alonzo, Soheil Meshinchi et al. · Journal of Clinical Oncology Open access 5 Aug 2014 489
28 Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG) Kirk R. Schultz, DJ Pullen, Harland N. Sather et al. · Blood Open access 26 Sep 2006 479
29 Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031 Kirk R. Schultz, Andrew J. Carroll, Nyla A. Heerema et al. · Leukemia Open access 20 Jan 2014 453
30 Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration Rebecka L. Meyers et al. · The Lancet Oncology Open access 21 Nov 2016 451
31 Augmented Post-Induction Therapy for Children with High-Risk Acute Lymphoblastic Leukemia and a Slow Response to Initial Therapy James B. Nachman, Harland N. Sather, Martha G. Sensel et al. · New England Journal of Medicine Open access 4 Jun 1998 451
32 Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study Brian V. Balgobind et al. · Blood Open access 15 Jun 2009 451
33 Residential Exposure to Magnetic Fields and Acute Lymphoblastic Leukemia in Children Martha S. Linet, Elizabeth Elliott Hatch, Ruth A. Kleinerman et al. · New England Journal of Medicine Open access 3 Jul 1997 422
34 International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee Peter F. Ambros, I.M. Ambros, G M Brodeur et al. · British Journal of Cancer Open access 28 Apr 2009 409
35 Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome Richard C. Harvey et al. · Blood Open access 11 Aug 2010 408
36 Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarrazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report Victor A. Levin, Pamela Silver, John F. Hannigan et al. · International Journal of Radiation Oncology*Biology*Physics Feb 1990 404
37 Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group Kenneth J. Cohen, Ian F. Pollack, T. Zhou et al. · Neuro-Oncology Open access 21 Feb 2011 402
38 Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710 Bayard L. Powell, Barry Kurt Moser, Wendy Stock et al. · Blood Open access 13 Aug 2010 400
39 Cancer in older adolescents and young adults: Epidemiology, diagnosis, treatment, survival, and importance of clinical trials W. Archie Bleyer · Medical and Pediatric Oncology 21 Dec 2001 394
40 ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma Scott C. Bresler, Daniel A. Weiser, Peter J. Huwe et al. · Cancer Cell Open access Nov 2014 394
41 Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine Edith A. Perez, Guillermo Luis Lerzo, Xavier B. Pivot et al. · Journal of Clinical Oncology Open access 3 Jul 2007 393
42 Adolescents and young adults with cancer Archie Bleyer, Troy Budd, Michael J. Montello · Cancer Open access 2006 390
43 The genetic basis and cell of origin of mixed phenotype acute leukaemia Thomas Alexander et al. · Nature Open access 11 Sep 2018 384
44 Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia Patrick Andrew Brown, Lingyun Ji, Xinxin Xu et al. · JAMA Open access 2 Mar 2021 381
45 Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma Julie R. Park, Susan G. Kreissman, Wendy B. London et al. · JAMA Open access 27 Aug 2019 369
46 Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group Bruce Bostrom · Blood 16 Jan 2003 362
47 Copy number variation at 1q21.1 associated with neuroblastoma Sharon J. Diskin et al. · Nature Open access Jun 2009 361
48 Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group Kenneth J. Cohen, Richard L. Heideman, T. Zhou et al. · Neuro-Oncology Open access 22 Feb 2011 349
49 Children's Oncology Group's 2013 blueprint for research: Neuroblastoma Julie R. Park, Rochelle Bagatell, Wendy B. London et al. · Pediatric Blood & Cancer 19 Dec 2012 347
50 Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial Kara Lynn Davis, Elizabeth Fox, Melinda S. Merchant et al. · The Lancet Oncology Open access 17 Mar 2020 344

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.